342 related articles for article (PubMed ID: 18708765)
1. alpha-synuclein degradation by autophagic pathways: a potential key to Parkinson's disease pathogenesis.
Xilouri M; Vogiatzi T; Vekrellis K; Stefanis L
Autophagy; 2008 Oct; 4(7):917-9. PubMed ID: 18708765
[TBL] [Abstract][Full Text] [Related]
2. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells.
Vogiatzi T; Xilouri M; Vekrellis K; Stefanis L
J Biol Chem; 2008 Aug; 283(35):23542-56. PubMed ID: 18566453
[TBL] [Abstract][Full Text] [Related]
3. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
[TBL] [Abstract][Full Text] [Related]
4. Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy.
Xilouri M; Vogiatzi T; Vekrellis K; Park D; Stefanis L
PLoS One; 2009; 4(5):e5515. PubMed ID: 19436756
[TBL] [Abstract][Full Text] [Related]
5. A new perspective in Parkinson's disease, chaperone-mediated autophagy.
Li B; Zhang Y; Yuan Y; Chen N
Parkinsonism Relat Disord; 2011 May; 17(4):231-5. PubMed ID: 21215675
[TBL] [Abstract][Full Text] [Related]
6. Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease.
Murphy KE; Gysbers AM; Abbott SK; Spiro AS; Furuta A; Cooper A; Garner B; Kabuta T; Halliday GM
Mov Disord; 2015 Oct; 30(12):1639-47. PubMed ID: 25594542
[TBL] [Abstract][Full Text] [Related]
7. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy.
Martinez-Vicente M; Talloczy Z; Kaushik S; Massey AC; Mazzulli J; Mosharov EV; Hodara R; Fredenburg R; Wu DC; Follenzi A; Dauer W; Przedborski S; Ischiropoulos H; Lansbury PT; Sulzer D; Cuervo AM
J Clin Invest; 2008 Feb; 118(2):777-88. PubMed ID: 18172548
[TBL] [Abstract][Full Text] [Related]
8. Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies.
Xilouri M; Brekk OR; Stefanis L
Mov Disord; 2016 Feb; 31(2):178-92. PubMed ID: 26813776
[TBL] [Abstract][Full Text] [Related]
9. The lysosomal membrane protein LAMP2A promotes autophagic flux and prevents SNCA-induced Parkinson disease-like symptoms in the Drosophila brain.
Issa AR; Sun J; Petitgas C; Mesquita A; Dulac A; Robin M; Mollereau B; Jenny A; Chérif-Zahar B; Birman S
Autophagy; 2018; 14(11):1898-1910. PubMed ID: 29989488
[TBL] [Abstract][Full Text] [Related]
10. Lysosomal degradation of alpha-synuclein in vivo.
Mak SK; McCormack AL; Manning-Bog AB; Cuervo AM; Di Monte DA
J Biol Chem; 2010 Apr; 285(18):13621-9. PubMed ID: 20200163
[TBL] [Abstract][Full Text] [Related]
11. VPS35 in Dopamine Neurons Is Required for Endosome-to-Golgi Retrieval of Lamp2a, a Receptor of Chaperone-Mediated Autophagy That Is Critical for α-Synuclein Degradation and Prevention of Pathogenesis of Parkinson's Disease.
Tang FL; Erion JR; Tian Y; Liu W; Yin DM; Ye J; Tang B; Mei L; Xiong WC
J Neurosci; 2015 Jul; 35(29):10613-28. PubMed ID: 26203154
[TBL] [Abstract][Full Text] [Related]
12. Impaired Autophagic-Lysosomal Fusion in Parkinson's Patient Midbrain Neurons Occurs through Loss of ykt6 and Is Rescued by Farnesyltransferase Inhibition.
Pitcairn C; Murata N; Zalon AJ; Stojkovska I; Mazzulli JR
J Neurosci; 2023 Apr; 43(14):2615-2629. PubMed ID: 36788031
[TBL] [Abstract][Full Text] [Related]
13. Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson's patient brain-derived α-synuclein.
Limegrover CS; Yurko R; Izzo NJ; LaBarbera KM; Rehak C; Look G; Rishton G; Safferstein H; Catalano SM
J Neurosci Res; 2021 Apr; 99(4):1161-1176. PubMed ID: 33480104
[TBL] [Abstract][Full Text] [Related]
14. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
15. Controlling the mass action of alpha-synuclein in Parkinson's disease.
Kim C; Lee SJ
J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
[TBL] [Abstract][Full Text] [Related]
16. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy.
Cuervo AM; Stefanis L; Fredenburg R; Lansbury PT; Sulzer D
Science; 2004 Aug; 305(5688):1292-5. PubMed ID: 15333840
[TBL] [Abstract][Full Text] [Related]
17. Glucocerebrosidase deficits in sporadic Parkinson disease.
Murphy KE; Halliday GM
Autophagy; 2014 Jul; 10(7):1350-1. PubMed ID: 24915553
[TBL] [Abstract][Full Text] [Related]
18. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.
Murphy KE; Gysbers AM; Abbott SK; Tayebi N; Kim WS; Sidransky E; Cooper A; Garner B; Halliday GM
Brain; 2014 Mar; 137(Pt 3):834-48. PubMed ID: 24477431
[TBL] [Abstract][Full Text] [Related]
19. Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy.
Yang Q; She H; Gearing M; Colla E; Lee M; Shacka JJ; Mao Z
Science; 2009 Jan; 323(5910):124-7. PubMed ID: 19119233
[TBL] [Abstract][Full Text] [Related]
20. Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment.
Poehler AM; Xiang W; Spitzer P; May VE; Meixner H; Rockenstein E; Chutna O; Outeiro TF; Winkler J; Masliah E; Klucken J
Autophagy; 2014; 10(12):2171-92. PubMed ID: 25484190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
